You are here: Industry Insights > Waylivra

News List

PTC Therapeutics Announces Waylivra Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome firstwordpharma
August 24, 2021
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS)
Waylivra, Tecentriq and more accepted by SMC pharmatimes
November 11, 2020
The Scottish Medicines Consortium has published guidance on eight new medicines, accepting seven of those and rejecting one for use by NHS Scotland in its November meeting.
NICE u-turn sees Akcea's Waylivra win NHS funding pharmatimes
September 21, 2020
Akcea Therapeutics UK's Waylivra (volanesorsen), the first and only therapy for Familial Chylomicronaemia Syndrome (FCS), will be funded on the NHS after all, following a u-turn by the National Institute for Health and Care Excellence (NICE).
Waylivra granted conditional marketing authorisation in Europe pharmatimes
May 09, 2019
Waylivra granted conditional marketing authorisation in Europe.